Selective targeting of adenovirus to αvβ3 integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies
- 31 May 2010
- journal article
- Published by Elsevier BV in International Journal of Pharmaceutics
- Vol. 391 (1-2), 155-161
- https://doi.org/10.1016/j.ijpharm.2010.02.032
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Integrins in angiogenesis and lymphangiogenesisNature Reviews Cancer, 2008
- Antiangiogenesis to treat cancer and intraocular neovascular disordersLaboratory Investigation, 2007
- Angiogenesis in life, disease and medicineNature, 2005
- VEGF as a Therapeutic Target in CancerOncology, 2005
- Adenovirus Binding to Blood Factors Results in Liver Cell Infection and HepatotoxicityJournal of Virology, 2005
- Targeted Adenovirus VectorsHuman Gene Therapy, 2004
- Retargeting of adenoviral infection to melanoma: Combining genetic ablation of native tropism with a recombinant bispecific single‐chain diabody (scDb) adapter that binds to fiber knob and HMWMAAInternational Journal of Cancer, 2003
- Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5Science, 1997
- Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vesselsCell, 1994
- Requirement of Vascular Integrin α v β 3 for AngiogenesisScience, 1994